ANVS Company Profile and Key Details

Annovis Bio, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.95. This means the shares are trading above this model’s fair value.

Annovis Bio, Inc. (NYSE:ANVS) closed at $1.39 USD, gaining $0.01 (0.72%) from the previous close of $1.38. The stock is currently mid-range between its 52-week high and low $1.32 and $5.50. With a market capitalization of about $59.13 million, Annovis Bio, Inc. is classified as a micro-cap and shows market-like volatility (beta ~1.24). Key stats such as the average daily volume over the past year has been around 852.43 thousand shares, trading with heavier-than-usual volume. Headquartered in Malvern, PA, Annovis Bio, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Maria L. Maccecchini, the company employs approximately 7 people and listed since January 29, 2020. Annovis Bio, Inc. is a clinical-stage biopharmaceutical company focused on pioneering treatments for neurodegenerative disorders.

Our AI price prediction model suggests that Annovis Bio, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 5.76%, with price expected at $1.47 by September 17, 2026, within a range of $1.39 to $1.53 3-Month Outlook: Projected rise of 66.91%, reaching $2.32 by December 02, 2026, with a range of $1.98 to $2.53. 1-Year Outlook: Projected gain of 74.82%, with price at $2.43 by September 03, 2027, within a range of $0.00 to $1.23.

Annovis Bio, Inc. (NYSE:ANVS) shares are down -19.36% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Annovis Bio, Inc. trading at a premium to the broader market with a P/E of -0.78. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $35.64, suggesting 2464.03% upside. Our AI forecast model points to short-term strength (5.76% over two weeks), a medium-term rise (66.91% over three months), and a longer-term gain (74.82% over one year), with expected trading ranges indicating moderate volatility.

Short-term trend indicators are mixed aligned (SMA20 9.8%, SMA50 -9.47%, SMA200 2.4%). The stock’s 14-day RSI is 52.54 (neutral), while the ATR of 0.23 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -49.27% below its high and over 151.35% above its low. Average 10-day trading volume of 1.32 million shares is significantly above the 3-month average of 879.34 thousand, indicating heightened recent market interest.

Annovis Bio, Inc. has 42.61 million shares outstanding. The public float is 35.32 million shares, elevated short interest at 12.79% of float. This equals 4.96 million shares. The short ratio is 8.09 days. Institutional investors hold 17.9% of the float. Insiders own 8.26%. Hoffman Michael B holds 3.29 million shares, Maccecchini Maria-Luisa has 1.21 million shares and White Mark K. has 56.18 thousand shares. Over the past six months, insider transactions show net buying. They sold 0.00 shares across 0 transactions.

Annovis Bio, Inc. generated EPS of -$1.48 over the past year. Five-year average earnings growth is -73.95%. Wall Street analysts project EPS growth of 18.51% annually over the next five years. The latest quarter delivered EPS of -$0.40. The next quarter is forecast at -$0.31. Next year's EPS is expected at $31.86. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 4 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $17.00 to $8.00. The high target offers 1123.02% upside. The low target suggests 475.54% downside. The mean target is $14.75. This offers 961.15% upside. Annovis Bio, Inc. earnings surprise history is a mixed track record. The quarter that ended August 14, 2026, missed forecasts by -11.76%. The prior quarter beat by 59.49%. Over the last six quarters, Apple has recorded several small beats. These include -31.91% in May 13, 2025.

Annovis Bio, Inc. trades at a P/E ratio of -0.78, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of -12.25 indicating negative book value, which may reflect financial stress. The P/FCF stands at -1.36, also above market averages.